Aerosolization Performance, Antitussive Effect and Local Toxicity of Naringenin-Hydroxypropyl-β-Cyclodextrin Inhalation Solution for Pulmonary Delivery

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Minyi Guan ◽  
Xuan Zeng ◽  
Rui Shi ◽  
Yuying Zheng ◽  
Weiyang Fan ◽  
...  
2020 ◽  
Vol 11 (SPL1) ◽  
pp. 259-261
Author(s):  
Aamir Khan ◽  
Rajni K. Gurmule

Vasavaleha is one of the best medicine given for respiratory diseases. Corona viruses typically affect the respiratory system, causing symptoms such as coughing, fever and shortness of breath. It also affects host immune system of human body. Spreading rate of this disease is very high. Whole world is seeking for the treatment which can uproots this diseases. There in no vaccine available till date against this pandemic disease. Ayurveda mainly focuses on prevention of diseases alongwith its total cure. Rajyakshma Vyadhi is MadhyamMarga Roga as per Ayurveda. It shows many symptoms such as Kasa, Shwasa etc. By overall view of Covid 19, shows its resemblance with Rajyakshma Vyadhi described in Ayurveda. Vasavaleha is a Kalpa which is described in Rogadhikara of Rajyakshma. It shows Kasahara, Shwashara properties. It consists of Vasa, Pipalli, Madhu and Goghrita. These components shows actions like bronchodilation, antitussive effect and many more other actions. Pipalli shows important Rasayana effect. So in present review, we have tried to focus on role of Vasavaleha in the management of Covid 19. This can be used as preventive as well as adjuvant medication in treating Covid 19. There is need of further clinical research to rule of exact action of Vasavaleha against Covid 19.


2018 ◽  
Vol 15 (5) ◽  
pp. 630-640 ◽  
Author(s):  
Hamed Vakilzadeh ◽  
Jaleh Varshosaz ◽  
Mohsen Minaiyan
Keyword(s):  

Soft Matter ◽  
2021 ◽  
Author(s):  
Amir Erfani ◽  
Abanoub Hanna ◽  
Payam Zarrintaj ◽  
Saeed Manouchehri ◽  
Katie Weigandt ◽  
...  

Many recent innovative treatments are based on monoclonal antibodies (mAbs) and other protein therapies. Nevertheless, sustained subcutaneous, oral or pulmonary delivery of such therapeutics are limited by the poor stability,...


2011 ◽  
Vol 02 (05) ◽  
pp. 567-575 ◽  
Author(s):  
Carlotta Marianecci ◽  
Luisa Di Marzio ◽  
Federica Rinaldi ◽  
Maria Carafa ◽  
Franco Alhaique

1995 ◽  
Vol 4 (5) ◽  
pp. 331-337 ◽  
Author(s):  
Ricardo J. Gonzalez-Rothi ◽  
Hans Schreier

Vaccine ◽  
2004 ◽  
Vol 22 (13-14) ◽  
pp. 1609-1615 ◽  
Author(s):  
Maytal Bivas-Benita ◽  
Krista E. van Meijgaarden ◽  
Kees L.M.C. Franken ◽  
Hans E. Junginger ◽  
Gerrit Borchard ◽  
...  

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Hongyun Zhao ◽  
Yee Chan-Li ◽  
Samuel L Collins ◽  
Yuan Zhang ◽  
Robert W Hallowell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document